Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surufatinib and Envafolimab in Recurrent/Metastatic HNSCC
NCT06876844Phase 2Recruiting
- Sponsor
- Shanghai Ninth People's Hospital
- Start
- Dec 2024
- Primary completion
- Sep 2027
- Modality
- Fragment-Derived Small Molecules, Monoclonal Antibodies, Allosteric Modulators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of surufatinib and envafolimab in head and neck squamous cell carcinoma (HNSCC), sponsored by Shanghai Ninth People's Hospital. Primary endpoint: Objective Response Rate at 1 year. Started Dec 2024; status: recruiting.
02
Drugs
surufatinibenvafolimab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT06876844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06876844.